Free press releases distribution network?

Agency / Source: Image Solutions, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



ISI Acquires Apyx, Inc. to Cement Leadership in Life Sciences Regulatory Consulting, Services and Software - Combination strengthens ISI’s footprint in the Northeast pharmaceutical corridor and positions the company for future success in dynamic global life sciences industry
ISI Acquires Apyx, Inc. to Cement Leadership in Life Sciences Regulatory Consulting, Services and Software

 

PRZOOM - /newswire/ - Whippany, NJ, United States, 2009/10/19 - Combination strengthens ISI’s footprint in the Northeast pharmaceutical corridor and positions the company for future success in dynamic global life sciences industry.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ISI, a leading provider of software and services for the life sciences industry, today announced that it has acquired Apyx, Inc. The merger adds muscle to ISI’s already-growing professional services business, which saw a 26 percent increase in sales from 2007 to 2008, and enhances the company’s broad range of offerings in submissions management and outsourcing. The two companies’ shared commitment to customer service and responsiveness make the merger a natural fit.

“This addition to ISI enhances our flexible and holistic suite of services and software to the regulatory space that is unmatched in the marketplace,” said Jinsoo Kim, President and CEO of ISI. “Industry leadership and experience from Apyx helps fuel our mission of helping bring life-changing therapies to market safely and efficiently. The two companies have shared a vision for years – now we are driving together to reach a common goal.”

ISI currently provides 13 out of the top 20 pharmaceutical companies with ongoing, repeat services. Over the last decade, the company has helped biopharmaceutical companies all over the world bring dozens of therapies through regulatory approval to patients in need. The acquisition helps ISI strengthen its capabilities to offer clients a mix of process, technology, data and operational services that respond to today’s complex submission environment.

“We are joining forces with ISI because there is a huge opportunity to leverage each other’s strengths,” said Ken VanLuvanee, CEO, President and Founder of Apyx, Inc. “With ISI’s deep resources and expertise in Europe and Asia, we will be able to address the diverse range of submission requirements across the globe.” Ken VanLuvanee joins ISI as Vice President of Global Professional Services, reporting to Paul Chung, Executive Vice President. VanLuvanee will be leading the effort to further expand ISI’s Professional Services capabilities, utilizing his prior experiences within the consulting business around document management, business process improvement, CDISC submission services and program management. Ken will continue to be an active contributor at various industry forums such as HL7, DIA, and across various standards’ development initiatives.

ISI makes the acquisition at a time of flux for the pharmaceutical industry. In the wake of transformational new regulations and a host of economic and competitive factors, life sciences firms are dealing with a complex global marketplace they have never seen before.

Diverse and ever-changing regulatory standards across regions, the need to expand into emerging markets, and increasing pressure to collaborate with partners and oversee local operations are all contributing to the new era of unparalleled complexity. With the acquisition of Apyx, ISI will deliver more efficient and standardized processes and systems, enable operational alignment around the globe, and facilitate a more effective exchange of information to help clients navigate these new challenges.

About Image Solutions, Inc. (ISI)
Founded in 1992, Image Solutions, Inc. (imagesolutions.com) is a proven market leader in providing submissions solutions, process services and consulting to Life Sciences companies as a way to improve clinical and regulatory processes that bring new medicines to market. ISI was among the first professional services firms to deliver electronic submissions to the industry and since has delivered thousands of electronic and eCTD submissions. ISI serves the top 50 pharmaceutical and biotech organisations as well as the top companies in other regulated industries.

ISI is a privately held company with headquarters in Whippany, New Jersey and operations throughout the U.S., Europe and Asia. ISI also remains committed to giving back to society and sharing its success with others by donating 10 percent of annual net profits to over 20 recognised charitable organisations.

Image Solutions, Inc., ISIToolBox, eCTDXPress, ISIPublisher and ISIRegTracker are trademarks or registered trademarks of Image Solutions, Inc. which may be registered in the United States and internationally. Other brand names may be trademarks or registered trademarks of others.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Image Solutions, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


ISI Acquires Apyx, Inc. to Cement Leadership in Life Sciences Regulatory Consulting, Services and Software

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Image Solutions, Inc. 
973-560-0404 info[.]imagesolutions.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Image Solutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Image Solutions, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  S&A Capital Partner Ltd

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today